“Celebrating Excellence in Patient Care, Education and Research”

Annual Report
July 1, 2014-June 30, 2015
The Division of Hematology/Oncology continues to be a vibrant, productive, and highly respected academic unit at the University of Michigan. With nearly 80 faculty and growing, the Division is one of the largest units in the Department of Internal Medicine. Our faculty are involved in bench to bedside research, from basic laboratory experiments to conducting experimental clinical treatments, with the goal of providing better treatment options for patients with cancer and hematologic disorders.

Since 2007, when I assumed the role of Division Chief, we have recruited over 40 faculty members across multiple disease areas and research interests. We are particularly proud of the growth of our junior faculty and their remarkable accomplishments. In the last five years, our faculty have been successful in obtaining numerous awards to support their research interests, including: NIH K-awards (3), NIH R01-awards (13), Leukemia & Lymphoma Society (8), American Society of Clinical Oncology (ASCO) Young Investigator Awards (4), American Cancer Society Awards (5), the V Foundation for Cancer Research (3), American Association for Cancer Research (2), Damon Runyon Cancer Research (2), American Society for Blood & Marrow Transplantation (3), Department of Defense (8), American Society of Hematology, numerous other peer-reviewed foundation awards, and 225 new clinical trials. Below are some additional statistics showing the tremendous growth of our activities.

The diverse composition of our faculty creates wonderful mentorship opportunities for our fellows across multiple disciplines and disease areas. We work with our trainees to ensure they have a strong mentorship team that will be highly committed to providing guidance for both research and career development. In addition to funding from the University of Michigan’s Graduate Medical Education Department, the trainees in our fellowship program are supported by the Veteran’s Administration, our NIH T32 Training Grant (five trainees pursuing careers in academic medicine), and the Elsa Pardee Foundation (two trainees pursuing careers in community cancer care). The majority of our graduating fellows have chosen to remain in academia, with nearly 75% of our graduating fellows in the last ten years now at an academic medical center.

In this report, you will find highlights of our current faculty and fellows. We celebrate the remarkable accomplishments of the Division of Hematology/Oncology and look forward to training the future leaders in academic medicine.

<table>
<thead>
<tr>
<th>FY14</th>
<th>FY15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Faculty (Instruction &amp; Clinical Tracks)</td>
<td>67</td>
</tr>
<tr>
<td>Faculty (Research)</td>
<td>17</td>
</tr>
<tr>
<td>External Funding (Directs)</td>
<td>$19.2M</td>
</tr>
<tr>
<td>Clinical Trial Accruals</td>
<td>458</td>
</tr>
<tr>
<td>Outpatient Visits</td>
<td>54,378</td>
</tr>
<tr>
<td>New Patients</td>
<td>6,230</td>
</tr>
<tr>
<td>Inpatient Admissions</td>
<td>2,046</td>
</tr>
<tr>
<td>Fellows</td>
<td>20</td>
</tr>
</tbody>
</table>

Kathleen A. Cooney, MD  
Frances and Victor Ginsberg Professor of Hematology/Oncology  
Professor of Internal Medicine and Urology  
Chief, Division of Hematology/Oncology  
Deputy Director, Cancer Clinical Services  
University of Michigan Comprehensive Cancer Center
Division Leadership

The Senior Advisory Team (pictured here) helps lead the strategic direction of the division in clinical care, research, education, service, and philanthropy.

The Division Leadership Team handles ongoing day-to-day management issues. This team is comprised of the division chief, Dr. Cooney, the associate chiefs, Drs. Reddy and Smith, and the division administrator, Julie Brabbs.

**Associate Chiefs**

- **Pavan Reddy, MD**
  Moshe Talpaz Professor of Translational Oncology
  Associate Chief of Research

- **David Smith, MD**
  Professor
  Associate Chief of Clinical Services

**Senior Advisors**

- **Daniel F. Hayes, MD, FASCO**
  Stuart B. Padnos Professor of Breast Cancer Research
  Senior Advisor for Philanthropy

- **Maha Hussain, MD, FACP, FASCO**
  Cis Maisel Professor of Oncology
  Senior Advisor for Clinical Research

- **Moshe Talpaz, MD**
  Alexander J. Trotman Professor for Leukemia Research
  Senior Advisor for Translational Research

---

**Julie Brabbs, MBA**
Division Administrator

**Kemp Cease, MD, MBA**
Professor
VA Section Chief

**Francis Worden, MD**
Professor
Fellowship Program Director
PATIENT CARE

57,687 Outpatient Visits
2,014 Inpatient Admissions
220 Bone Marrow Transplants
$16.3M Patient Care Revenue
6,344 New Patient Clinic Visits

BY THE NUMBERS—FY15

269 Journal Articles in CY 2014
99 Journal Articles in CY 2015 through July
(Source: Scopus)

ABOUT US

85 Research & Clinical Faculty
84 Laboratory Research Staff
37 Dedicated Administrative Staff
10 Buildings Occupied
38K sq. ft. of Research Space

EDUCATION

20 Hematology/Oncology Fellows
23 Regularly Scheduled CME Activities Provided

GRANTS & CLINICAL TRIALS

227 Proposals Submitted
71 Clinical Trials Opened
468 Clinical Trial Accruals
$22M Direct Funds

FY15 Newly Funded Grants

American Cancer Society Scholars (2)
American Society of Clinical Oncology (ASCO) Young Investigator Award
Breast Cancer Research Foundation (BCRF) (2)
Damon Runyon Cancer Research Foundation
Leukemia & Lymphoma Society
NIH K Award
NIH U10 (LAPS)
NIH R01
Ovarian Cancer Research Fund
Pardee Foundation (2)
Prostate Cancer Foundation
U.S. Department of Defense
V Foundation for Cancer Research
New Faculty

**Patrick Burke, MD**—Lecturer.
Dr. Burke earned his BS in Biology from Providence College in Rhode Island. He matriculated at the Mount Sinai School of Medicine in New York where he earned his medical degree. He then completed a residency in Internal Medicine at the University of Chicago Medical Center, followed by a year serving as a Chief Resident. He recently completed his Hematology/Oncology fellowship at Memorial Sloan Kettering Cancer Center in New York, where his clinical and research interests focused on leukemia, particularly adult acute lymphoblastic leukemia (ALL). He performed clinical research regarding the role of asparaginase and pediatric-inspired therapeutic regimens in adult ALL, as well as investigating therapies that spare cytotoxic chemotherapy in older adult Philadelphia chromosome-positive ALL. Dr. Burke is currently focusing his research on early phase clinical trials in acute leukemias and is treating patients with hematologic malignancies.

**Leslie Fecher, MD**—Associate Professor.
Dr. Fecher joined the faculty from Indiana University School of Medicine's Simon Cancer Center. She completed her BA in Biochemistry at Rice University in Houston, and earned her medical degree from Indiana University School of Medicine. She completed her residency at University of Texas Southwestern in Dallas, followed by an Oncology fellowship at Johns Hopkins' Sidney Kimmel Comprehensive Cancer Center in Baltimore. Dr. Fecher was an Assistant Professor at the Abramson Cancer Center in Philadelphia for four years where she held a secondary appointment in Dermatology. She then joined the faculty at Indiana University. Dr. Fecher's research and clinical focus is on melanoma and other advanced cutaneous tumors.

**Aki Morikawa, MD, PhD**—Lecturer.
Dr. Morikawa earned her BMus and MMus in Piano Performance at the Boston University School of Arts. She then completed an MPH in Epidemiology & Biostatistics at the Boston University School of Public Health, followed by a PhD in Epidemiology, and her MD from Emory University in Atlanta. Dr. Morikawa completed her Internal Medicine residency at Emory University followed by a Medical Oncology fellowship at Memorial Sloan Kettering in New York. She has already earned numerous honors, most recently the ASCO/Conquer Cancer Foundation Gianni Bonadonna Breast Cancer Research Fellowship in 2013. Dr. Morikawa’s research interest is in metastatic breast cancer with a focus in brain and leptomeningeal metastases. She is treating breast cancer patients.

**Phillip Palmbos, MD, PhD**—Lecturer.
Dr. Palmbos is a graduate of the Physician Scientist Training Program at the University of Michigan, a combined residency and fellowship program through the American Board of Internal Medicine (ABIM). His PhD research focused on DNA repair. His current laboratory research focuses on understanding the molecular mechanisms driving bladder cancer formation using transgenic and xenograft models as well as in vitro work. He is currently working in the laboratory of his mentor, Dr. Diane Simeone, in the Translational Oncology Program. His clinical focus is GU malignancy and he primarily sees patients with bladder and prostate cancers.
The division also welcomed back two faculty members:

Erica Campagnaro, MD—Associate Professor.
Dr. Campagnaro attended Louisiana State University where she earned her BA in French, followed by an MD at Louisiana State University Health Sciences Center in New Orleans, Louisiana. She completed a residency in Internal Medicine at the University of Texas Medical Branch in Galveston, Texas, followed by a year as Chief Resident. She completed her Hematology/Oncology fellowship at the University of Texas M.D. Anderson Cancer Center, where her clinical and research interests focused on myeloma. She continued that focus as a Clinical Lecturer at the University of Michigan from 2007-2009. She then joined the faculty at Case Western Reserve University, leading their myeloma program. Dr. Campagnaro’s clinical and research focus is on improving outcomes in patients with multiple myeloma.

Bryan Schneider, MD—Associate Professor.
Dr. Schneider is focused on experimental therapeutics in lung/esophageal cancer and participates in the Phase I Program. He serves as Associate Medical Director of the Cancer Center Ambulatory Care Unit (ACU) in charge of the Adult Infusion Centers and the Ambulatory Treatment Center. Dr. Schneider was a fellow at the University of Michigan from 2002-2005, and was with the division as an assistant professor until 2008. He has spent the last six years at New York Presbyterian Hospital Weill Medical College of Cornell University in New York.

Faculty Distinction

Ronald J. Buckanovich, MD, PhD, installed as Thomas H. Simpson Collegiate Professor

Ronald John Buckanovich, MD, PhD, earned an undergraduate degree in genetics and biochemistry at Cornell University in 1990, a PhD from the Rockefeller University in 1996, and a medical degree from Cornell in 1998. During his thesis research with Robert Darnell, MD, PhD, Dr. Buckanovich characterized the cellular target of an autoimmune neurologic disease associated with breast and ovarian cancer. This work resulted in a novel diagnostic test that is currently used in clinical practice.

It was during his Hematology/Oncology fellowship at the University of Pennsylvania that Dr. Buckanovich worked with George Coukos, MD, PhD, and began to focus his research on defining the ovarian cancer microenvironment to identify novel therapeutic targets. Dr. Buckanovich joined the faculty of the University of Michigan in 2006. Here he has continued his efforts to define the cellular compartments of cancer in order to identify novel diagnostic tests and therapeutic agents for women’s cancer with an emphasis on ovarian cancer. Currently the laboratory is focused on understanding the cellular interactions in the tumor vascular/cancer stem cell niche. Recent studies have identified a means to inactivate BRCA gene expression in cancer cells to sensitize them to both chemotherapy and a new class of molecular targeted therapies called PARP-inhibitors. His lab is also currently developing two new therapies targeting cancer stem cells—one to prevent cancer cell metastasis and another to prevent disease recurrence.

Dr. Buckanovich also maintains a busy clinical practice specializing in the treatment of ovarian and uterine cancers. He is currently the principal investigator on two clinical trials. He holds four patents, two for novel therapeutics being developed here. The author or co-author of 37 original research articles, he was awarded a three-year Clinical Investigator Award from the Damon Runyon Cancer Research Foundation in 2008 as well as the New Innovator/Directors Award from the National Institutes of Health that same year.
Faculty Distinction

James M. Rae, PhD, installed as Thomas H. Simpson Collegiate Professor of Cancer Research

James M. Rae, PhD, holds a joint appointment in the University of Michigan Department of Internal Medicine and the Department of Pharmacology. He received a BS in biology from the University of Pittsburgh and a PhD in pharmacology from Georgetown University, where he trained with Marc E. Lippman, MD, and David A. Flockhart, MD, PhD, in the Lombardi Cancer Center. Dr. Rae was recruited to the University of Michigan in 2001 as a research investigator.

Dr. Rae’s combined experiences with breast cancer research and molecular pharmacology in Drs. Lippman’s and Flockhart’s laboratories, respectively, led him to enter the field of personalized medicine.

Dr. Rae has played a significant role in the field of breast cancer. He has developed an extensive network of collaborators locally, nationally, and internationally, to study how inherited genetic variants affect the way patients activate and eliminate certain drugs, in particular anti-estrogen agents such as tamoxifen and aromatase inhibitors.

Dr. Rae is the executive officer of translational research for SWOG, the largest clinical oncology cooperative trials group in the United States. He is responsible for overseeing the group’s translational medicine efforts and biorepository, and also serves as a SWOG representative on the National Cancer Institute’s Group Banking Committee. Dr. Rae also co-chairs the Translational Breast Cancer Research Foundation’s Endocrine Resistance Working Group.

Dr. Rae serves on the editorial boards of biomedical research journals and is a member of the American Association of Cancer Research, the American Society of Clinical Oncology, the American Association for the Advancement of Science, and the National Clinical Trials Network.

A creative and dedicated teacher, Dr. Rae has also served as mentor to several graduate students in the Department of Pharmacology.

Muneesh Tewari, MD, PhD, installed as Ray and Ruth Anderson—Laurence M. Sprague Memorial Research Professor

Muneesh Tewari, MD, PhD, is a world-renowned pioneer and leader in the field of blood-based microRNA biomarkers. After earning his bachelor’s degree in biochemistry from Case Western Reserve University in 1990, he came to the University of Michigan where he earned both a doctorate in cell and molecular biology and a medical degree in 1997. He stayed on for his internship and residency in internal medicine.

Dr. Tewari then moved to Boston where he completed his Oncology fellowship at Dana-Farber Cancer Institute. Following a postdoctoral research fellowship in systems biology and genetics at Dana-Farber Cancer Institute/Harvard Medical School, he joined the faculty of the Fred Hutchinson Cancer Research Center in Seattle in 2005. It was during his time at Harvard that Dr. Tewari first became intrigued by microRNAs (miRNAs). In Seattle, he focused his attention on miRNAs. His research has revealed that miRNAs are released from cancer cells into the bloodstream and circulate in a highly stable form, which has led to burgeoning interest in circulating miRNAs as biomarkers for cancer and other diseases. He continues to investigate both the biology and clinical applications of extracellular RNA, including minimally invasive methods for disease monitoring using human biofluids.

Dr. Tewari has served as principal investigator for numerous grants from the NIH, the DOD, academic institutions and foundations. He has received multiple awards for innovation, including the Damon-Runyon Rachleff Innovation Award, which he received in 2009, and the Presidential Early Career Award for Scientists and Engineers awarded by President Barack Obama in 2010.

A creative and dedicated mentor to his trainees, past and present, Dr. Tewari also serves on a wide variety of professional panels and committees, presents his work nationally and internationally, and maintains a clinical practice as an attending oncologist. In 2014, eager to take his work to the next step, he returned to his alma mater, a place where researchers in molecular biology and clinical oncology can intersect powerfully with those in bioengineering, tech transfer, bioinformatics, computer science, and health economics and policy.
Dean’s Awards

2014 Dean’s League of Research Excellence

Ivan Maillard, MD, PhD, was inducted into the Dean’s League of Research Excellence, which celebrated the phenomenal success of the U-M Medical School’s elite research faculty. Selected individuals are those that have demonstrated research excellence in all or one of the following areas: collaborations and team science, publications, seminal discoveries, entrepreneurial endeavors, and national/international prominence in his/her field.

2014 Dean’s Faculty Awards

Clinical and Health Services Research Award
Moshe Talpaz, MD
David C. Smith, MD

Outstanding Clinician Award
Gregory P. Kalemkerian, MD

Scott D. Gitlin, MD, was selected as a member of the Hematology Board of the American Board of Internal Medicine (ABIM).

Maha Hussain, MD, FACP, was honored as the 2015 Giant of Cancer Care in Genitourinary Cancer. The Giants of Cancer Care program, sponsored by Onclive, celebrates individuals who have achieved landmark success within the field of oncology and is the premier oncology award in the country aiming to recognize and celebrate physicians who have made significant contributions to the cure and treatment of those living with cancer.

Daniel F. Hayes, MD, FASCO, has been elected President of the American Society of Clinical Oncology (ASCO) for the term beginning in June 2016.

Mark S. Kaminski, MD, received a distinction of a unique sort. A grateful patient has named an Ann Arbor building in his honor. The building, named “The Mark” is currently under construction on Liberty Street.

John Krauss, MD, is chairman elect of the American Society for Clinical Oncology (ASCO) Health Information Technology Work Group.

Pavan Reddy, MD, has been elected to the Association of American Physicians (AAP). AAP membership is comprised of investigators who focus on basic, disease-oriented, patient-oriented, or epidemiology research. The goals of its members include the pursuit of medical knowledge, and the advancement through experimentation and discovery of basic and clinical science and their application to clinical medicine.

Muneesh Tewari, MD, PhD, has been inducted into the American Society for Clinical Investigation (ASCI). The ASCI represents active physician-scientists who are at the bedside, the research bench, and at the blackboard. The society elects up to 80 new members annually for their significant research accomplishments. Members must be 50 years of age or younger at the time of election. Therefore, election reflects accomplishments by members early in their careers.

Catherine Van Poznak, MD, is chair of the Lifelong Learning Subcommittee of ASCO, and chair elect of ASCO’s Continuing Medical Education Subcommittee.

Shaomeng Wang, PhD, has been named a Fellow of the National Academy of Inventors (NAI). Election as an NAI fellow is a professional distinction given to academic inventors who have demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development and the welfare of society. Dr. Wang is an inventor on 38 issued U.S. patents and several pending patent applications, many of which have been licensed to three startup companies: Ascenta Therapeutics, Ascentage Pharma and OncoFusion Therapeutics, which Wang co-founded.
Faculty Distinction

Department of Internal Medicine Awards

Academiae Laureati Medici

The Department of Internal Medicine’s Clinical Excellence Society, Academiae Laureati Medici, recognizes those faculty who exude and demonstrate clinical excellence towards their patients and colleagues. Anne Schott, MD was inducted into the society. Mark Kaminski, MD was re-elected as President, and Gregory Kalemkerian, MD was elected as Councilor.

Internal Medicine Faculty Award

Grace Chen, MD, PhD, received the Jerome Conn Excellence in Research Award. The Jerome Conn Award is given for outstanding research investigation by a physician scientist at the assistant professor level. It is named after Jerome Conn, the former division chief of endocrinology who was the first to describe primary hyperaldosteronism later known as Conn’s syndrome. Past Hematology/Oncology Division recipients of this award include Drs. Kathleen Cooney and Pavan Reddy.

Internal Medicine Staff Award

Joann Sherman, HemOnc Fellowship administrator, received an Excellence in Administration award.
Monika Burness, MD, received funding from MICHR (Michigan Institute for Clinical and Health Research) for her pilot project titled “Targeting Cancer Stem Cells via IL-6 Signaling in Triple-Negative Breast Cancer.” This study will lay the foundation for pivotal early phase clinical trials to evaluate the safety and efficacy of cytokine-targeted therapy for patients with TNBC, specifically with a novel gp130 inhibitor. Dr. Burness also received the inaugural University of Michigan Comprehensive Cancer Center Dr. Frank Limpert Clinical Scholar Award. She was selected based on her novel and promising work in breast cancer stem cells. Additionally, she received a University of Michigan Health System Lefkofsky Family Foundation Scholar Award.

Phillip Palmbos, MD, PhD, focuses his research on understanding the molecular drivers of bladder cancer formation. He has identified the oncogene, ATDC/TRIM29, as important driver in invasive basal bladder tumors where it promotes tumor growth and invasion. He was awarded the ASCO Young Investigator Award for this work in 2014, and received the Miriam Gleberman Young Investigator Award from the Bladder Cancer Advocacy Network (BCAN). Dr. Palmbos’ lab is located at the NCRC in the Translational Oncology Program.

Brian Parkin, MD, focuses his research on translational genomics of acute myelogenous leukemia (AML), specifically the association of genomic aberrations with relapsed and chemotherapy refractory AML, as well as the development of novel methods of genomic minimal residual disease detection. He published “Integrated Genomic Profiling, Therapy Response, and Survival in Adult Acute Myelogenous Leukemia” in the journal Clinical Cancer Research this year, which examined the interplay of gene mutations and DNA copy number aberrations and their effect on clinical outcomes. He was the recipient of the American Society of Blood and Marrow Transplantation New Investigator Award in 2013 and received a grant from the Pardee Foundation in 2014 to further his work studying rare variant detection and clonal dynamics of AML in complete remission.
Fellowship Program

ACGME Fellowship Program in Hematology/Oncology

Trainees rotate through inpatient services and outpatient continuity clinics and have the opportunity to focus on a research project with a faculty mentor. Dr. Francis Worden directs this program, along with Drs. Dale Bixby and Patrick Hu, who serve as associate directors. We thank Dr. Ronald Buckanovich for his service and leadership as associate director for the last six years.

We prepare our fellows to be creative and productive contributors as both cutting-edge researchers and astute clinicians. This is evidenced by a number of our trainees having abstracts accepted for publication or presentation at the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), or the American Association for Cancer Research (AACR) annual meetings.

Our program combines well-rounded clinical training with the opportunities to work with world-class investigators in a collegial environment. Our combined Hematology/Oncology three-year clinical training program features a diversified patient care experience on busy hematology and oncology inpatient services, consultative services, the bone marrow transplantation program, and outpatient clinics at the University of Michigan Comprehensive Cancer Center and the nearby Ann Arbor Veterans Affairs Medical Center.

Educational Programs

Undergraduate and Graduate Students

Many of our faculty are involved in the education of students interested in scientific research careers through the U-M Medical School’s Undergraduate Research Opportunity Program (UROP) which is designed to build partnerships with first/second year students and faculty researchers. Our faculty also participate in:

- Program in Biomedical Sciences (PIBS)
- Medical Scientist Training Program (MSTP)
- Graduate Program in Immunology
- Graduate Program in Cancer Biology
- Biological Sciences Scholars Program (BSSP)
- Global Health Initiative/Global Reach

Many of our faculty also have established both formal and informal mentorship relationships with undergraduate, graduate and post-doctoral students.

Accreditation Council for Graduate Medical Education (ACGME) Residency Program in Internal Medicine

Our faculty teach residents in multiple settings, including inpatient services, outpatient clinics, and in clinical and laboratory research activities.

U-M Medical Students: Dr. Asra Ahmed leads the Hematology sequence for second year medical students.

Faculty Development: Drs. Asra Ahmed and Rashmi Chugh both serve on the Internal Medicine Education Committee which is charged with developing a faculty development process centered on education.
HemOnc Fellows

Graduating Fellow Destinations

University of Michigan Cancer Center
Elizabeth Davis, MD
Sumana Devata, MD
Raymond Esper, MD, PhD
Vedran Radojcic, MD

Washington University
Leonel Hernandez Aya, MD

Stanford University Palliative Fellowship
Joshua Wilfong, DO

Fellowship website: http://www.med.umich.edu/intmed/hemonc/fellows/index.html
Patient Care

CLINICAL SERVICES

Inpatient Clinical Services
University Hospital
- Oncology (Internal Medicine Residency Service)
- Hematology (Internal Medicine Residency Service)
- Chemotherapy Service
C.S. Mott Children’s and Von Voigtlander Women’s Hospital (C&W)
- Blood and Marrow Transplant (Non-Residency Service)
- Hematology (Non-Residency Service)
- Acute Leukemia

Outpatient Clinical Services
Comprehensive Cancer Center, Ann Arbor
- CCC Team 1 (Adult Hematology)
- CCC Team 2 (Medical Oncology)
- CCC Team 3 (GU Oncology)
- CCC Team 5 (Breast Oncology)
- CCC Team 6 (Melanoma, Genetics)
- CCC Team 7 (Gynecological Oncology)
- Infusion Services
C. S. Mott Children’s & Von Voigtlander Women’s Hospital (C&W)
- Adult Blood & Marrow Transplant
- Adult Acute Leukemia Clinic
- Infusion Services
Canton & Northville Health Centers
- Hematology
- Oncology
- Infusion Services

New Clinic Locations

Northville—opened July 15, 2014. The new Northville Health Center opened July 15, 2014. The new facility boasts 100,000 square feet of clinical and diagnostic space. An estimated 160 patients were seen in FY15 at this new location where a full suite of Hematology and Oncology services are offered. Dr. Albert Quiery oversees hematology patients and Dr. John Krauss oversees oncology patients. Dr. Krauss is Medical Director, Canton and Northville Infusion Services.

In March of 2015, our Adult Acute Leukemia Clinics moved to the C.S. Mott Children’s and Von Voigtlander Women’s Hospital to more closely align with the services provided there by the Blood and Marrow Transplant Group.

New Thyroid Cancer Research website

A new website devoted to thyroid cancer research at the U-M Health System called ThyCare (THYroid CANcer REsearch), has been developed to give visibility to the program and information to patients. The website highlights the staff, faculty, and students working on thyroid cancer projects, as well as their publications, and research news. The thyroid cancer research group is represented by two teams, which are profiled on the website: the Thyroid Cancer Health Services Research Team, headed by Megan Haymart, MD, and the Thyroid Cancer Clinical Trials Team, headed by Francis (Frank) Worden, MD.

The web address for the new site is: https://sites.google.com/a/umich.edu/thycare/home.
About the Program

These faculty are working on drug discovery, pharmacogenetics and pharmacogenomics.

Shaomeng Wang, PhD, runs a substantial laboratory on the NCRC campus conducting drug design, synthesis, and development of small-molecule therapeutics for the treatment of human cancers, as well as development of new computational methods of drug design.

Selected Publications


Muneesh Tewari, MD, PhD holds a secondary appointment with the Department of Biomedical Engineering and is also a member of the Bioinformatics Institute and Center for Computational Medicine & Bioinformatics (CCMB). Dr. Tewari’s laboratory is best known for its discoveries in the biology of extracellular microRNAs. His groundbreaking research bridges disciplines including molecular biology, clinical oncology, bioengineering and computer science. His team is focused on reducing cancer mortality by developing a next generation of biomarker approaches to enable earlier detection of cancer, more effective use of new therapies such as immunotherapy, and improved non-invasive methods for long-term follow-up and care of cancer survivors. They are accomplishing this by bringing together concepts and approaches from molecular oncology, engineering, and information technology, to enable cancer detection and monitoring to be done non-invasively at home, in an internet-connected way over extended periods of time.

Dr. Tewari received a $3.3 million U01 grant from the NIH Extracellular RNA Communication Program to characterize extracellular RNA in body fluids from healthy individuals using next generation sequencing methods. The purpose of this five-year project is to discover the universe of extracellular RNAs present in healthy people, as well as to study the absorption of RNA ingested in food into the circulation of healthy individuals. Co-Investigators on the study include Drs. Hui Jiang, Saravana Dhanasekaran and Arul Chinnaiyan at U-M, as well as Drs. Florian Hladik, Johanna Lampe and Julie McElrath the Fred Hutchinson Cancer Research Center in Seattle, WA.

Selected Publication

About the Program

This past year brought many changes to the Phase I program. There has been a significant increase in patients being referred to open slots in accruing Phase I clinical trials. Monthly meetings are utilized to further develop and refine this novel program.

Selected Publications


Phase I Faculty

Monika Burness, MD, is investigating novel therapies to improve treatment options for patients with breast cancer.

Rashmi Chugh, MD, is actively engaged in clinical trials in connective tissue oncology and experimental therapeutics.

Bryan Schneider, MD, has a strong background in clinical and translational studies with interests in the area of diagnosis and novel treatment for lung cancer.

Tycel Phillips, MD, is conducting experimental therapeutics with a focus on hematologic malignancies.

David Smith, MD, is a physician investigator conducting experimental therapeutics in addition to his other clinical and leadership responsibilities.

Moshe Talpaz, MD, is a clinical investigator conducting experimental therapeutics in addition to his other clinical and leadership responsibilities.
About the Program

Our 21 active program faculty engage in patient care, educational activities, and research related to benign and malignant hematology. Among our specialists are faculty who focus on specific disease groups: blood and coagulation disorders, myeloproliferative neoplasms, myelofibrosis, lymphoma, leukemia and myeloma.

Our researchers are exploring exciting opportunities in the areas of disease prevention, understanding predictive and diagnostic biomarkers related to disease progression, and identification of molecular targets to develop novel therapeutic treatments of patients with hematologic diseases.

Selected Publications


Asra Ahmed, MD, is a medical hematologist with a clinical focus on lymphoma, myeloma and coagulation disorders. Dr. Ahmed also directs the second year medical student hematology sequence.

Dale Bixby, MD, PhD, specializes in clinical research to develop therapeutic trials for the treatment of leukemia. He also serves as co-director of the fellowship program for the division and is the director of Inpatient Hematology.

Paula Bockenstedt, MD, specializes in general hematology with emphasis in autoimmune hematologic disorders and disorders of hemostasis such as ITP, antiphospholipid syndrome, thrombophilia and hemophilia. Dr. Bockenstedt is the director of the Adult Coagulation Disorders Program and participates in multi-center studies of thrombosis, antiphospholipid antibody syndrome (APLS) and congenital hemophilic disorders.

Patrick Burke, MD—Dr. Burke is currently focusing his research on early phase clinical trials in acute leukemias and is treating patients with hematologic malignancies in the Cancer Center.

Erica Campagnaro, MD, is focused on clinical research to improve outcomes in patients with multiple myeloma.

Mark Chiang, MD, PhD, sees patients with hematologic malignancies. His research program is focused on leukemia, notch signaling, hox transcription factors, leukemia stem cells, and mouse modeling.

Craig Cole, MD, specializes in multiple myeloma and consultative general hematology. His research is focused on developing clinical trials for multiple myeloma.

Scott Gitlin, MD, treats patients with all types of malignant and non-malignant hematologic disorders, including bleeding and clotting diseases and other hematologic disorders. His laboratory research focuses on the role of viruses in oncogenesis.

Mark Kaminski, MD, treats lymphoma patients and conducts clinical research focused on developing therapeutic trials for the treatment of lymphoma. He is internationally known for his work in radioimmunotherapy (RIT). Dr. Kaminski is the director of the Multidisciplinary Lymphoma Clinic.

Rami Khoriaty, MD, is pursuing research focused on understanding the pathophysiology of congenital dyserythropoietic anemias and the process of erythropoiesis. Dr. Khoriaty treats patients with myeloproliferative neoplasms and other myeloid neoplasms.

Lisa Kujawski, MD, is a hematologist with a clinical and research focus on the treatment of myelodysplastic syndromes and acute/chronic leukemias, palliative medicine and symptom management.
Qing Li, MD, PhD, conducts research focused on signaling pathways in normal hematopoietic stem cells and leukemic stem cells. She treats patients with hematologic malignancies.

Ivan Maillard, MD, PhD, is a member of the Life Sciences Institute where he researches hematopoiesis, hematopoietic stem cells, Notch signaling, and T-cell immunity. He treats patients with hematological malignancies and directs the University of Michigan’s Leukemia Program.

Sami Malek, MD, treats patients with leukemia. His laboratory focuses on genetics and bio-markers related to chronic lymphocytic leukemia (CLL) and lymphoma and the identification of targeted therapeutic treatment options.

Marie Huong T. Nguyen, MD, treats patients with hematologic malignancies, with a clinical focus on myeloproliferative neoplasms (MPNs). Her research focuses on early phase clinical trials in myelofibrosis and other MPNs.

Tycel Phillips, MD, treats patients with lymphoma. He conducts clinical research related to lymphomas and Phase I/II studies.

Albert Quiery, Jr., MD, is the director of General Hematology in the Cancer Center, and the Team One Leader in the Cancer Center. His clinical focus is in the areas of immunohematology, hemoglobinopathies, hemostasis, and thrombosis. His academic interest is in bioethics and the medical humanities. Dr. Quiery sees patients at the Cancer Center and the new Northville Health Center.

Samuel Silver, MD, PhD, FASCO, specializes in bleeding disorders, platelet dysfunction, porphyria, myeloproliferative and myelodysplastic disorders, as well as quality of care. Dr. Silver also serves as Assistant Dean for Research, U-M Medical School.

Suman Sood, MD, treats patients and conducts research related to thrombosis, acquired hemophilia, bio-markers of venous thrombosis, novel anticoagulants, and bleeding disorders in women.

Moshe Talpaz, MD, treats leukemia patients and conducts clinical research on hematologic malignancies, particularly leukemia, to develop novel therapeutic options for patients.

Ryan Wilcox, MD, PhD, treats patients with lymphomas. His research is focused on understanding the T-cell lymphomas and the role of host immunity in lymphoproliferative disorders.
**About the Program**

The Adult Blood & Marrow Transplantation (BMT) Program, is headed by **Pavan Reddy, MD**, the Moshe D. Talpaz Professor of Translational Oncology. He is also serving as the clinical director of Adult BMT.

The Division welcomed **Claudia Diaz-Byrd** as the new BMT Program Administrator in 2014.

The BMT Program performs over 220 transplants per year. Our BMT researchers continue to maintain a prominent presence at national meetings, including the American Society of Blood and Marrow Transplantation/Center for International BMT Research and the American Society of Hematology.

The Program has piloted an Ambulatory Treatment Center (ATC) which concentrated care of early post-transplant for autologous patients through day 30 and through day 100 for allogeneic patients. This has impacted outcomes with a reduction in readmission rate.

The Program includes an extracorporeal photopheresis (ECP) unit that is one of the largest in the world.

---

**Selected Publications**


**BMT researchers opened three new clinical trials and enrolled 39 patients**
Steven Goldstein, MD, specializes in stem cell transplantation and conducts clinical research in the treatment of hematologic malignancies and the prevention and treatment of GVHD.

John Magenau, MD, specializes in stem cell transplantation and conducts clinical research in the treatment of complications and prevention of relapse after BMT.

Brian Parkin, MD, specializes in the treatment of acute myeloid leukemia (AML) and bone marrow transplantation. He conducts laboratory research focusing on genomic biomarker discovery and validation as well as determining the mechanisms of therapy resistance and relapse of AML before and after allogeneic stem cell transplantation.

Attaphol Pawarode, MD, specializes in stem cell transplantation and conducts clinical research in BMT for lymphoid diseases.

Pavan Reddy, MD, specializes in stem cell transplantation and conducts translational and laboratory research focused on blood and marrow transplantation, specifically in GVHD and graft-versus-leukemia (GVL).

Mary Mansour Riwes, DO, specializes in stem cell transplantation and conducts clinical research in leukemia and hematopoietic stem cell transplantation.


**Gastrointestinal (GI) Oncology**

**About the Program**

Seven division faculty clinicians and researchers, working with colleagues across other disciplines, are part of the Gastrointestinal (GI) Oncology Program. The program is focused on the care and treatment of patients with colorectal, pancreatic, gastric, and liver malignancies.

The research program is just as collaborative as the clinical program. It includes more than 40 researchers from 18 departments who have made significant strides in researching GI cancers.

Their goal has been focused upon what biologic, genetic and/or molecular processes have to take place to give rise to the development of GI cancer.

In 2010, the program received a Gastrointestinal Oncology Specialized Program of Research Excellence (SPORE) grant from NIH. The overall goal of this SPORE is to reduce mortality associated with GI cancers, specifically colorectal and pancreatic cancers. This goal will be achieved through identifying and developing interventions to modify molecular based common cancer-associated carcinogenesis and cancer progression processes and linking them to human investigations.

**Selected Publications**


Dean Brenner, MD, Kutsche Memorial Chair of Internal Medicine Professor, specializes in GI oncology and cancer prevention. He is the principal investigator of an NCI-sponsored GI SPORE as well as an NCI Early Detection Research Network (EDRN) grant.

Grace Chen, MD, PhD, conducts laboratory research investigating the role of the immune system and gut bacteria in colon cancer development, and also specializes in the treatment of patients with GI malignancies.

Patrick Hu, MD, PhD, conducts laboratory research focused on c. elegans as a model for studying the pathogenesis of cancer. His clinical interest is in colorectal cancer.

John Krauss, MD, sees general oncology patients at the Canton and Northville clinics, and colon cancer patients at the Cancer Center. Dr. Krauss is Medical Director, Infusion Services, Canton & Northville Health Centers.

Vaibhav Sahai, MD, MS, focuses on patients with GI cancers. His research focus lies in experimental therapeutics in pancreatic and biliary tract cancer via a molecular-biology based approach in the laboratory with the aim to perform clinical and translational research.

Christine Veenstra, MD, specializes in patients with GI malignancies. Her research is focused on identifying factors that impact the quality of colorectal cancer care, and on developing interventions to improve the receipt of high quality care.

Mark Zalupski, MD, conducts clinical research to develop therapeutic treatment options for GI cancers and is a senior leader in the GI Clinic.

GI-Oncology researchers opened seven clinical trials in FY15 and enrolled 57 patients.
Genitourinary (GU) Oncology

About the Program

The UMCCC has an NIH SPORE for Prostate Cancer which provides research support for a substantial amount of translational research conducted by faculty from multiple disciplines: Urology, Surgery, Radiation Oncology and Pathology.

Selected Publications


GU-Oncology researchers opened ten clinical trials in FY15 and enrolled 56 patients
Ajjai Alva, MD, treats patients and conducts clinical research focused on genitourinary (GU) oncology, including prostate, bladder and kidney cancers. He currently has a U-M Michigan Institute for Clinical & Health Research (MICHR) K Award supporting his research.

Megan Caram, MD, conducts research investigating minimizing the harm done to patients with cancer-directed therapies and understanding the factors that guide treatment decisions. She is currently studying the variation in care of castration-resistant prostate cancer, including non-evidence-based use of therapies, and investigating the clinical and nonclinical factors that guide treatment decisions, including patients’ access to care and provider effects on various treatment decisions.

Kathleen Cooney, MD, Frances and Victor Professor of Hematology/Oncology, conducts research related to prostate cancer genetics and treats patients with prostate cancer. She is a PI of an NCI T32, Co-PI of the U-M Prostate Cancer SPORE, PI of a DOD award, and member of the steering committee for the International Consortium for Prostate Cancer Genetics.

Maha Hussain, MD, FACP, FASCO, Cis Maisel Professor of Oncology, professor of Medicine and Urology, treats patients with prostate, bladder and testes cancer. Her clinical research is focused on the development of novel therapeutics for prostate and bladder cancer and is funded by federal, foundation and pharmaceutical grants and contracts.

Phillip Palmbos, MD, PhD, is conducting research on DNA repair. His current laboratory research focuses on understanding the molecular mechanisms driving bladder cancer formation using transgenic and PDX models as well as in vitro work. His clinical focus is GU malignancy and he primarily sees patients with bladder and prostate cancers in the Cancer Center.

Bruce Redman, DO, treats patients and conducts clinical research related to GU cancers and melanoma. His research is directed at the development of novel therapeutic treatment options for both GU cancers and melanoma.

David Smith, MD, treats patients with testicular, prostate and bladder cancer and advanced solid tumors. His research interest is in novel therapeutics and clinical trial design. He is the PI of multiple clinical trials aimed at the development of new therapeutic options for patient with advanced solid tumors.
Head & Neck and Thoracic Oncology

About the Program

The UMCCC has an NIH SPORE for Head and Neck (H&N) cancer which strengthens the program by providing support for exciting new research projects.

Head and neck cancer researchers work closely with colleagues across other disciplines: otolaryngology, radiation oncology, and speech pathology.

Our thoracic oncology faculty focus on conducting research in close collaboration with colleagues in thoracic surgery, pulmonary, gastroenterology, radiology and pathology.

Dr. Ramnath conducts a clinical research program at the Veterans Affairs Ann Arbor Healthcare System (VAAAHS).

Selected Publications


Khaled Hassan, MD, MS, treats patients with lung cancer. His research lab is focused on lung cancer stem cells and establishing targeted therapy to improve patient outcomes.

Gregory Kalemkerian, MD, conducts clinical research focused on developing therapeutic trials for the treatment of lung cancer. He is a senior leader in the Thoracic Oncology Clinic.

Nithya Ramnath, MD, has a joint appointment with VAAHS. She treats patients with lung cancers. Her laboratory research interests include studying regulation of vitamin D metabolism in smoking-related lung cancers. Additionally, she has a research interest in determining ex-vivo predictors of drug sensitivity (for targeted therapy) using circulating tumor cells derived from patients. Her clinical research interests include studying determinants of response to immunotherapy in lung cancer. At the VAAHS, she is co-PI of a Lung Cancer Screening Demonstration Project and site PI for Precision Oncology Program for Veterans with cancer.

Bryan Schneider, MD, is focused on experimental therapeutics in lung/esophageal cancer and participates in the Phase I Program. He serves as Associate Medical Director of the Cancer Center Ambulatory Care Unit (ACU) in charge of the Adult Infusion Centers and the Ambulatory Treatment Center.

Susan Urba, MD, is the Medical Director of the UMCCC Symptom Management & Supportive Care Program. She conducts clinical research related to esophageal cancer, head and neck cancer, and palliative care.

Francis Worden, MD, conducts clinic research directed at the development of novel therapeutic treatment options for patients with adrenal and head and neck cancers.
**About the Program**

We have twelve faculty dedicated to women’s cancers in the Division of Hematology/Oncology focusing on breast cancer and gynecologic oncology. Academic interests span the spectrum of disease, including risk and prevention, adjuvant systemic therapy, new drug development, tumor biomarker generation and evaluation, quality of life studies, and health sciences research.

**Selected Publications**


Breast & GynOnc Faculty

Ronald Buckanovich, MD, PhD, researches ovarian tumor vasculature and stem cell niche, with the goal of developing therapeutic treatments which disrupt cancer stem cell growth promotion pathways. He treats patients with gynecologic cancers.

Monika Burness, MD, is investigating novel therapies to improve treatment options for breast cancer. She treats patients in the breast cancer clinic.

Jennifer Griggs, MD, MPH, treats patients in the breast cancer clinic. Her health services research program addresses quality of care and patient-physician communication and decision making.

Daniel F. Hayes, MD, Stuart B. Padnos Professor of Breast Cancer Research, is co-director of the UMCCC Breast Oncology Program. He conducts clinical and translational research to discover tumor markers and develop therapeutic treatments for patients with breast cancer.

N. Lynn Henry, MD, PhD, treats patients in the breast cancer clinic. Her research addresses why patients experience side effects from treatments, as well as potential ways to prevent or manage the side effects. Additionally, she investigates treatments for early stage and metastatic cancer.

Sofia Merajver, MD, PhD, researches the molecular genetics of breast cancer, BRCA1 gene functions, angiogenesis, and cancer risk assessment. She is also the co-director of the UMCCC Breast Oncology Program and director of the Breast and Ovarian Cancer Risk and Evaluation Program.

Aki Morikawa, MD, PhD, has a research interest in metastatic breast cancer, focusing on brain and leptomeningeal metastases. She is treating breast cancer patients.

James Rae, PhD, is a scientist whose lab focuses on drug metabolism, pharmacogenetics, pharmacogenomics, and biomarker identification and characterization, particularly as they apply to the prediction of breast cancer treatment response.

Max Wicha, MD, Distinguished Professor of Oncology, is the founding director of the UMCCC. Dr. Wicha’s group was part of the team that first identified cancer stem cells in human breast cancers, the first in any solid tumor. His laboratory has developed many of the techniques and assays used to study these cells and to elucidate the pathways which regulate their behavior.

Anne Schott, MD, treats patients in the breast cancer clinic. She conducts clinical research aimed at developing novel therapies for the treatment of breast cancer.

Jeffrey Smerage, MD, PhD, is Chief Medical Information Officer in the Cancer Center. He specializes in the care of breast cancer patients and conducts clinical research in the areas of tumor markers and developmental therapeutics.

Catherine Van Poznak, MD, treats patients in the breast cancer clinic. Her research focuses on breast cancer and its relationship to bone including osteoporosis, biomarker identification, and bone metastases.
**Sarcoma**

**About the Program**

The Division of Hematology/Oncology has a strong cadre of faculty devoted to sarcoma: **Drs. Laurence Baker, Rashmi Chugh, and Scott Schuetze**. They specialize in the care of patients with sarcomas as well as conducting clinical research to develop novel therapeutic treatment options.

The Sarcoma Survivorship Clinic was opened last year to address the unique medical and psychosocial needs of young adult and adult sarcoma survivors. This sarcoma survivorship program is a unique coordination of care between pediatric and adult sarcoma providers as well as across medical subspecialties. Our aim is to prevent morbidity/lethality of chronic medical conditions and to improve the quality of life in pediatric, adolescent, young adult, and older adult survivors.

---

**Faculty**

**Laurence Baker, DO**, Collegiate Professor of Cancer Developmental Therapeutics, conducts clinical trials and is interested in survivorship for patients with soft tissue and bone sarcomas.

**Rashmi Chugh, MD**, treats patients with sarcoma. She is focused on clinical trials related to sarcoma and experimental therapeutics.

**Scott Schuetze, MD, PhD**, treats patients with sarcoma. He conducts clinical research focused on the development of therapeutic treatment options for patients with sarcoma. Dr. Schuetze is also Medical Director of the UMCCC Clinical Trials Office.

---

**Selected Publications**

**Cobain EF**, Chinnaiyan AM, Kurzrock R, **Baker LH**. Genomic profiling of cancers of unknown primary site: The next steps. JAMA Oncol. 2015 Jul; 1(4): 542. PMID 26181268

**Chugh R**, Griffith KA, Davis EJ, Thomas DG, Zavala JD, Metko G, Brockstein B, Undevia SD, Stadler WM, **Schuetze SM**. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Ann Oncol. 2015 Jul;26(7):1459-64. Epub 2015 Apr 9. PMID 25858498


---

**Researchers opened five clinical trials in FY15 and enrolled 36 patients**
Endocrine Oncology

About the Program

Dr. Francis Worden collaborates with colleagues across the UMCCC to treat patients with endocrine cancers. The Multidisciplinary Endocrine Oncology Clinic is one of only a few US medical centers recognized as an international center of excellence for the treatment of adrenal cancer. It is also designated as a UMHS Destination Center, an endeavor by the Health System to become the provider of choice for patients around the world.

Selected Publication


Researchers enrolled one patient on clinical trials during FY15

Melanoma

About the Program

The UMCCC Melanoma Multidisciplinary Clinic, designated as the NCI’s Midwest referral center, offers patients efficient and expedited care regardless of their disease stage. The skin cancer program was the first Destination Center in UMHS. Drs. Fecher, Lao and Redman work with colleagues across 15 departments to provide outstanding patient care and offer novel therapeutic treatments for patients with melanoma.

Faculty

Leslie Fecher, MD, has a research and clinical focus on melanoma and other advanced cutaneous tumors.

Chris Lao, MD, conducts experimental therapeutics related to melanoma chemoprevention and treats patients with melanoma.

Bruce Redman, DO, conducts clinical research related to kidney cancer and melanoma to develop novel therapeutic treatment options.

Researchers opened three clinical trials in FY15 and enrolled 30 patients
**Veterans Affairs Program**

### About the Program

The Veterans Affairs Ann Arbor Healthcare System (AAVA) Hematology-Oncology Section operates in close partnership with the Division of Hematology/Oncology at the University of Michigan in all realms of their shared missions, with clinical services at the AAVA centered around Oncology and Hematology outpatient clinics and inpatient consultative services.

The Section provides the programmatic foundation and leadership for the Multidisciplinary Cancer Program at the AAVA, which this year again received full accreditation from the American College of Surgeons Commission on Cancer, with full commendation in all seven available categories.

The AAVA is the largest single supporter of the Hematology/Oncology Fellowship Program, enabling very diverse educational experiences characterized by immersive patient care and research experiences.

The Section is actively developing its clinical research capabilities and options as it expands in response to enormous growth in patients coming from throughout Michigan and neighboring states.

The faculty are engaged in diverse research pursuits including clinical, translational, outcomes and laboratory research.

### Faculty

#### Kemp Cease, MD, MBA

Section Chief, cares for patients across the spectrum of oncology. His research is in the rational design of vaccines as informed by target molecular structure.

#### Dean Brenner, MD

holds the Kutsche Memorial Professorship of Internal Medicine, and actively conducts research in gastrointestinal oncology and cancer prevention.

#### Megan Caram, MD

is clinically focused on genitourinary cancer, and is actively engaged in outcomes research in these patients.

#### Scott Gitlin, MD

is engaged in the care of patients with all types of malignant and non-malignant hematologic disorders, and in advancing subspecialty education.

#### Lisa Kujawski, MD

has a clinical and research focus on myelodysplasia, acute and chronic leukemias, and palliative medicine.

#### Jon Oscherwitz, MD

is focused on laboratory research in the development of novel immunotherapeutics and vaccines for priority infectious diseases and malignancies.

#### Tycel Phillips, MD

is a physician investigator focusing on experimental therapeutics in hematologic malignancies.

#### Nithya Ramnath, MD

is focused on the clinical care of lung cancer patients and has research interests in biomarkers for prognostic, predictive, and translational use in lung cancer.

#### Christine Veenstra, MD, MSHP

specializes in gastrointestinal malignancies and is working to identify factors impacting the quality of colorectal cancer care.
# Our FY15 Faculty Roster

## Research Assistant Professor
- Longchuan Bai, PhD
- Jianyong Chen, PhD
- Chao-Yie Yang, PhD

## Assistant Research Scientist
- Liu Liu, PhD
- Ming Luo, PhD
- Sean P. McDermott, PhD
- Luke Peterson, PhD
- Yaping Sun, MD, PhD

## Research Investigator
- Angelo Aguilar, PhD
- Costanza Paoletti, MD
- Tomomi Toubai, PhD
- Haibin Zhou, PhD
- Yongyou Zhu, PhD

## Professor
- Laurence H. Baker, DO
- Dean E. Brenner, MD
- Kathleen A. Cooney, MD
- William D. Ensminger, MD, PhD*
- Scott D. Gitlin, MD
- Jennifer J. Griggs, MD
- Daniel F. Hayes, MD
- Maha Hussain, MD
- Gregory Kalemkerian, MD
- Mark S. Kaminski, MD
- Sofia Merajver, MD, PhD
- Pavan Reddy, MD
- Bruce G. Redman, MD
- Anne F. Schott, MD
- Scott M. Schuetze, MD
- Samuel M. Silver, MD, PhD
- David C. Smith, MD
- Moshe Talpaz, MD
- Susan Urba, MD
- Manuel Valdivieso, MD
- Shao meng Wang, PhD
- Max S. Wicha, MD
- Francis P. Worden, MD
- Mark M. Zalupski, MD

## Associate Professor
- Dale L. Bixby, MD, PhD
- Paula Bockenstedt, MD
- Ronald J. Buckanovich, MD, PhD
- Erica Campagnaro, MD *
- Kemp B. Cease, MD
- Rashmi Chugh, MD
- Leslie Fecher, MD *
- Steven C. Goldstein, MD
- N. Lynn Henry, MD
- Patrick J. Hu, MD, PhD
- Christopher D. Lao, MD
- Ivan Patrick Maillard, MD
- Sami Malek, MD
- James M. Rae, PhD
- Nithya Ramnath, MD
- Jeffrey B. Smerage, MD
- Bryan Schneider, MD *
- Muneesh Tewari, MD, PhD
- Catherine H. Van Poznak, MD

## Assistant Professor
- Asra Z. Ahmed, MD
- Ajjai S. Alva, MD
- Grace Y. Chen, MD, PhD
- Mark Chiang, MD, PhD
- Craig E. Cole, MD
- Khaled Hassan, MD
- John C. Krauss, MD
- Lisa A. Kujawski, MD
- Marie Huong T. Nguyen, MD
- Attaphol Pawarode, MD
- Albert Quiery, MD
- Mary Riwes, DO
- Vaihab Sahai, MD, MS
- Suman Sood, MD
- Ryan Wilcox, MD, PhD

## Lecturer
- Patrick Burke, MD *
- Monika Burness, MD
- Megan V. Caram, MD
- Rami Khoriaty, MD
- Aki Morikawa, MD, PhD *
- Philip Palmbos, MD, PhD *
- Brian Parkin, MD
- Tycel Phillips, MD
- Christine M. Veenstra, MD

---

*New Faculty in FY15

*Emeritus Faculty